Open AccessRole of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease
Author(s) -
Eric R. Kallwitz,
Alan McLachlan,
Scott J. Cotler
Publication year - 2008
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.14.22
Subject(s) - nonalcoholic fatty liver disease , cirrhosis , medicine , peroxisome proliferator activated receptor , fatty liver , insulin resistance , endocrinology , pathogenesis , peroxisome proliferator activated receptor alpha , hepatocellular carcinoma , peroxisome proliferator , receptor , nuclear receptor , biology , disease , insulin , biochemistry , transcription factor , gene
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPAR alpha and PPAR gamma to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH.